NASDAQ:RUBY

Rubius Therapeutics Stock Forecast, Price & News

$25.20
-0.13 (-0.51 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$23.50
$25.36
50-Day Range
$22.26
$28.43
52-Week Range
$4.20
$38.71
Volume3.16 million shs
Average Volume1.27 million shs
Market Capitalization$2.25 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.57
30 days | 90 days | 365 days | Advanced Chart
Receive RUBY News and Ratings via Email

Sign-up to receive the latest news and ratings for Rubius Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Rubius Therapeutics logo

About Rubius Therapeutics

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.53 out of 5 stars

Medical Sector

535th out of 2,100 stocks

Biological Products, Except Diagnostic Industry

80th out of 198 stocks

Analyst Opinion: 2.1Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Rubius Therapeutics (NASDAQ:RUBY) Frequently Asked Questions

Is Rubius Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Rubius Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RUBY, but not buy additional shares or sell existing shares.
View analyst ratings for Rubius Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Rubius Therapeutics?

Wall Street analysts have given Rubius Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Rubius Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Rubius Therapeutics' next earnings date?

Rubius Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Rubius Therapeutics
.

How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics, Inc. (NASDAQ:RUBY) announced its quarterly earnings data on Monday, May, 10th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.03.
View Rubius Therapeutics' earnings history
.

How has Rubius Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Rubius Therapeutics' stock was trading at $6.55 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RUBY stock has increased by 284.7% and is now trading at $25.20.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RUBY?

4 brokerages have issued 1 year price objectives for Rubius Therapeutics' shares. Their forecasts range from $20.00 to $40.00. On average, they anticipate Rubius Therapeutics' share price to reach $28.33 in the next twelve months. This suggests a possible upside of 12.4% from the stock's current price.
View analysts' price targets for Rubius Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Rubius Therapeutics' key executives?

Rubius Therapeutics' management team includes the following people:
  • Mr. David R. Epstein, Exec. Chairman (Age 59, Pay $495k)
  • Dr. Pablo J. Cagnoni Ph.D., M.D., CEO, Pres & Director (Age 58, Pay $1.01M)
  • Mr. Laurence A. Turka M.D., Chief Scientific Officer (Age 63, Pay $704.94k)
  • Dr. Christina M. Coughlin B.S., M.D., Ph.D., Chief Medical Officer (Age 51, Pay $700.97k)
  • Mr. Jose I. Carmona, CFO, Principal Accounting Officer & Treasurer (Age 49)
  • Ms. Joanne M. Protano, Sr. VP of Fin. & Operations (Age 52)
  • Mr. Spencer Fisk, Sr. VP of Manufacturing & CTO
  • Ms. Lori Melancon, Chief Corp. Affairs Officer
  • Ms. Elhan Webb C.F.A., VP of Investor Relations
  • Ms. Maiken Keson-Brookes, Chief Legal Officer & Corp. Sec. (Age 48)

What is Pablo Cagnoni's approval rating as Rubius Therapeutics' CEO?

12 employees have rated Rubius Therapeutics CEO Pablo Cagnoni on Glassdoor.com. Pablo Cagnoni has an approval rating of 91% among Rubius Therapeutics' employees. This puts Pablo Cagnoni in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Rubius Therapeutics' key competitors?

What other stocks do shareholders of Rubius Therapeutics own?

When did Rubius Therapeutics IPO?

(RUBY) raised $200 million in an IPO on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is Rubius Therapeutics' stock symbol?

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

Who are Rubius Therapeutics' major shareholders?

Rubius Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Flagship Pioneering Inc. (43.11%), Baillie Gifford & Co. (5.78%), BlackRock Inc. (4.48%), JPMorgan Chase & Co. (2.79%), Federated Hermes Inc. (1.63%) and Victory Capital Management Inc. (1.48%). Company insiders that own Rubius Therapeutics stock include Christina M Coughlin, Christopher L Carpenter, David R Epstein, Maiken Keson-Brookes, Pablo J Cagnoni, Robert Langer and Ventures Fund Iv Gene Flagship.
View institutional ownership trends for Rubius Therapeutics
.

Which major investors are selling Rubius Therapeutics stock?

RUBY stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Caas Capital Management LP, Renaissance Technologies LLC, Ameriprise Financial Inc., Russell Investments Group Ltd., Millennium Management LLC, Nuveen Asset Management LLC, and Alliancebernstein L.P.. Company insiders that have sold Rubius Therapeutics company stock in the last year include David R Epstein, and Maiken Keson-Brookes.
View insider buying and selling activity for Rubius Therapeutics
or view top insider-selling stocks.

Which major investors are buying Rubius Therapeutics stock?

RUBY stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Federated Hermes Inc., Deerfield Management Company L.P. Series C, BlackRock Inc., State of Michigan Retirement System, Voloridge Investment Management LLC, Flagship Pioneering Inc., and Compagnie Lombard Odier SCmA. Company insiders that have bought Rubius Therapeutics stock in the last two years include Christina M Coughlin, David R Epstein, Pablo J Cagnoni, and Ventures Fund Iv Gene Flagship.
View insider buying and selling activity for Rubius Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Rubius Therapeutics?

Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rubius Therapeutics' stock price today?

One share of RUBY stock can currently be purchased for approximately $25.20.

How much money does Rubius Therapeutics make?

Rubius Therapeutics has a market capitalization of $2.25 billion. The company earns $-167,730,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis.

How many employees does Rubius Therapeutics have?

Rubius Therapeutics employs 231 workers across the globe.

What is Rubius Therapeutics' official website?

The official website for Rubius Therapeutics is www.rubiustx.com.

Where are Rubius Therapeutics' headquarters?

Rubius Therapeutics is headquartered at 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139.

How can I contact Rubius Therapeutics?

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]


This page was last updated on 6/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.